Analyst Price Targets — HCAT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 8, 2025 12:11 pm | — | Evercore ISI | $3.00 | $2.90 | TheFly | Health Catalyst price target lowered to $3 from $4 at Evercore ISI |
| October 8, 2025 10:41 am | — | KeyBanc | $4.00 | $2.85 | TheFly | Health Catalyst price target lowered to $4 from $5 at KeyBanc |
| August 29, 2025 10:38 am | Richard Close | Canaccord Genuity | $5.00 | $3.65 | TheFly | Health Catalyst price target lowered to $5 from $9 at Canaccord |
| August 29, 2025 10:38 am | — | Summit Redstone Partners | $5.00 | $3.65 | TheFly | Health Catalyst price target lowered to $5 from $9 at Canaccord |
| April 16, 2025 11:02 am | Scott Schoenhaus | KeyBanc | $5.00 | $3.75 | TheFly | Health Catalyst price target lowered to $5 from $7 at KeyBanc |
| March 6, 2025 12:10 pm | — | Stephens | $5.00 | $4.43 | TheFly | Health Catalyst price target lowered to $5 from $7 at Stephens |
| January 14, 2025 7:36 pm | Sean Dodge | RBC Capital | $7.00 | $6.98 | TheFly | Health Catalyst price target lowered to $7 from $9 at RBC Capital |
| September 3, 2024 7:23 am | Richard Close | Canaccord Genuity | $11.00 | $7.29 | StreetInsider | Canaccord Genuity Reiterates Buy Rating on Health Catalyst Inc. (HCAT) |
| August 26, 2024 7:18 am | Jessica Tassan | Piper Sandler | $11.00 | $7.19 | StreetInsider | Health Catalyst Inc. (HCAT) PT Lowered to $11 at Piper Sandler |
| August 8, 2024 6:44 am | Jeff Garro | Stephens | $7.00 | $5.48 | StreetInsider | Health Catalyst Inc. (HCAT) PT Lowered to $7 at Stephens |
Latest News for HCAT
Albert to Sharpen Focus on Improving Cost and Operational Efficiency, Clinical Quality, and Consumer Experience in Healthcare Health Catalyst Board to be Reduced to Five Directors Immediately Prior to the 2026 Annual Meeting SALT LAKE CITY, Feb. 18, 2026 /PRNewswire/ -- Health Catalyst, Inc. (Nasdaq: HCAT) ("Health Catalyst" or the "Company"), a leading provider of data and analytics technology and services to…
Health Catalyst (HCAT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Health Catalyst (HCAT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Health Catalyst (NASDAQ: HCAT - Get Free Report) and Healthcare Triangle (NASDAQ: HCTI - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings. Profitability This table compares Health Catalyst and
Health Catalyst (HCAT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for HCAT.
U.S. House Trading
No House trades found for HCAT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.